Foghorn Therapeutics Announces Upcoming Investor Conference Participation

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. ROST
2. WMT
3. AAP
4. HD
5. SFNC

6. FMG:AU
7. AVAH
8. JHX
9. FSUGY
10. ANF

Get Alerts FHTX Hot Sheet

Price: $7.01 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced management's participation in the following investor conferences. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Cowen's 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHAThursday, June 2nd, 10:30 a.m. ETPlease find a link to the fireside chat here.

Jefferies Healthcare ConferenceWednesday, June 8th, 1:30 p.m. ETPlease find a link to the fireside chat here.

Goldman Sachs 43rd Annual Global Healthcare ConferenceMonday, June 13th, 3:20 p.m. PTPlease find a link to the fireside chat here.

A webcast of the panel can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com and will be available for up to 90 days.

About Foghorn TherapeuticsFoghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies.

Contact:

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)[email protected]

Michael Lampe, ScientPR (Media)[email protected]

Hans Vitzthum, LifeSci Advisors (Investors)[email protected]